Search Results for: 19

— SYN-004 Degraded IV Ceftriaxone in Gastrointestinal Tract without Affecting Antibiotic Levels in the Bloodstream — — First Patients Dosed in Phase 2b Proof-of-Concept Clinical Trial for SYN-004 — — SYN to Host Microbiome Clinical Program Seminar in NYC on Thursday, December 10, 2015 — ROCKVILLE, Md., Dec. 1, 2015 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE […]

— Company Commenced Third Party Analysis of Reported Data — ROCKVILLE, Md., Nov. 25, 2015 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE MKT: SYN), a clinical stage company focused on developing therapeutics to protect the gut microbiome while targeting pathogen-specific diseases, announced today that Rhonda Voskuhl, M.D., Professor, Department of Neurology, Jack H. Skirball Chair in Multiple

— Adds to Existing International Patent Estate Directly Related to SYN-010 — — SYN to Host Microbiome Clinical Program Seminar in NYC on Thursday, December 10, 2015 — ROCKVILLE, Md., Nov. 24, 2015 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE MKT: SYN), a clinical stage company focused on developing therapeutics to protect the gut microbiome while targeting

— Event to Highlight Company’s Two Phase 2 Clinical Programs: Treatment of Irritable Bowel Syndrome with Constipation and Prevention of C. difficile Infection — — Scheduled for Thursday, December 10, 2015 — ROCKVILLE, Md., Nov. 19, 2015 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE MKT: SYN), a clinical-stage company focused on developing therapeutics to protect the gut

— Initiated Phase 2b Proof-of-Concept Clinical Trial for the Prevention of C. difficile Infection and Antibiotic Associated Diarrhea — — Initiated Second Phase 2 Clinical Trial to Evaluate the Sustainability of Reduced Methane Production in Patients with Irritable Bowel Syndrome with Constipation — — Conference Call Today, November 5, 2015, at 4:30 p.m. EST —

— The University of Texas at Austin Receives Grant from the Bill & Melinda Gates Foundation — ROCKVILLE, Md. and AUSTIN, Texas, Oct. 21, 2015 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE MKT: SYN), a clinical-stage company focused on developing therapeutics to protect the microbiome while targeting pathogen-specific diseases, and its Pertussis academic collaborator, The University of

— Company’s SYN-010 Program to Reduce the Impact of Methane Gas in the Gut Currently in Phase 2 Clinical Trials — ROCKVILLE, Md., Oct. 20, 2015 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE MKT: SYN), a clinical-stage company focused on developing therapeutics to protect the microbiome while targeting pathogen-specific diseases, announced that experimental results supporting the proposed

— Conference Call Scheduled for Thursday, November 5, 2015 at 4:30 p.m. EST — ROCKVILLE, Md., Oct. 19, 2015 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE MKT: SYN), a clinical-stage company focused on developing therapeutics to protect the microbiome while targeting pathogen-specific diseases, intends to release its financial results for the three and nine months ended September

— Trial to Evaluate the Ability of SYN-010 to Sustain the Reduction of Methane Production in the Gut for Patients who have Completed First Phase 2 Clinical Trial of SYN-010 — — Methane Production is Perceived as the Underlying Cause of Pain, Bloating and Constipation Associated with IBS-C — ROCKVILLE, Md., Oct. 8, 2015 /PRNewswire/

— Manufacturing Executive Served Most Recently in Leadership Positions at Merck &Co. — — Appointment Reflects Company’s Focus on Preparing for Late-Stage Clinical Trials — ROCKVILLE, Md., Oct. 1, 2015 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE MKT: SYN), a clinical-stage company focused on developing therapeutics to protect the microbiome while targeting pathogen-specific diseases, announced that Raymond